04, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Noom's leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
IV Nutrient Therapy Semaglutide reduces food intake
Type 2 diabetes or prediabetes is another strong qualifying condition
Microdosing Retatrutide is a user-driven approach that has not been tested in controlled settings
In clinical trials: About 5% of people taking Ozempic reported constipation About 24% of people taking Wegovy reported constipation GLP-1 medications can slow digestion and reduce how often you go, especially in people with a higher body weight
Using both provides dual cardiovascular protection, limits individual risk factors, and helps determine whether this matters for your treatment strategy